Nearly 2 billion "bone care needles"!

On April 6, the official website of the State Food and Drug Administration showed that China Resources Shuanghe was approved to market as a concentrated solution of zoledronic acid for injection, which was produced in imitation of Category 4
.
According to data from Minet.
com, in 2020, the sales of terminal zoledronic acid injections in Chinese public medical institutions exceeded 1.
8 billion yuan
.
Source: The official website of the State Food and Drug Administration Zoledronic acid is a bisphosphonate compound that specifically acts on bone, can inhibit bone resorption caused by increased osteoclast activity, and is used for the treatment of patients with solid tumor bone metastases and multiple Bone damage in patients with myeloma is commonly referred to as a "bone protector" on the market
.
Novartis' zoledronic acid was launched in China in 2005, mainly divided into two types: water injection and powder injection.
In 2018, Novartis announced that zoledronic acid preparation (powder injection) was withdrawn from the Chinese market, and water injection still maintained domestic supply
.
According to the data from Minet.
com, the sales of zoledronic acid injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have fluctuated in recent years.
In 2020, its sales exceeded 1.
8 billion yuan, with a year-on-year increase of 2.
86% in the first half of 2021
.
Sales of terminal zoledronic acid in public medical institutions in China (unit: RMB 10,000) Source: Minet For the production approval of acid concentrated solution, the products of 5 companies, namely China Resources Shuanghe, Chia Tai Tianqing Pharmaceutical, Yangzijiang, Qilu, and Renhe Yikang, have been reviewed, of which Chia Tai Tianqing is the first one
.
Among similar domestic products, Amgen's denosumab was approved for import in May 2019.
The drug can make up for the renal function requirement of zoledronic acid and can be injected subcutaneously
.
In the first half of 2021, the sales of terminal denosumab in public medical institutions in China exceeded 60 million yuan, a year-on-year increase of 1111.
45%
.
However, in terms of price, zoledronic acid still has a great advantage.
Affected by the monopoly of Amgen, the price of denosumab is still difficult to be suppressed to the greatest extent like zoledronic acid.

.
According to industry reports, after medical insurance reimbursement of zoledronic acid concentrated solution for injection can reach about 300 yuan, which is lower than the price of 1060 yuan for denosumab
.
In the upcoming seventh batch of centralized collection, zoledronic acid injections (1ml: 1mg, 5ml: 4mg, 4mg, 100ml: 4mg and 100ml: 5mg) have been included in the scope of centralized collection.
Companies such as Pharma and Kelun have already won admission tickets
.
In addition to being used in oncology, zoledronic acid has many applications in surgery and orthopedics
.
Affected by the aging population, the country has carried out national procurement for artificial joints.
With the promotion of joint replacement surgery, similar drugs such as zoledronic acid will usher in a new round of patient demand in the future, and the market growth can be expected in the future
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Note: The statistics are as of April 8, if there are any omissions, please correct me!